ES2306278T3 - Perla enterica recubierta que comprende ixabepilona. - Google Patents

Perla enterica recubierta que comprende ixabepilona. Download PDF

Info

Publication number
ES2306278T3
ES2306278T3 ES05824194T ES05824194T ES2306278T3 ES 2306278 T3 ES2306278 T3 ES 2306278T3 ES 05824194 T ES05824194 T ES 05824194T ES 05824194 T ES05824194 T ES 05824194T ES 2306278 T3 ES2306278 T3 ES 2306278T3
Authority
ES
Spain
Prior art keywords
enteric
coated
pearl
active ingredient
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05824194T
Other languages
English (en)
Spanish (es)
Inventor
Ismat Ullah
Gary James Wiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2306278T3 publication Critical patent/ES2306278T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES05824194T 2004-11-18 2005-11-17 Perla enterica recubierta que comprende ixabepilona. Expired - Lifetime ES2306278T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18
US628970P 2004-11-18

Publications (1)

Publication Number Publication Date
ES2306278T3 true ES2306278T3 (es) 2008-11-01

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05824194T Expired - Lifetime ES2306278T3 (es) 2004-11-18 2005-11-17 Perla enterica recubierta que comprende ixabepilona.

Country Status (25)

Country Link
US (1) US20060153917A1 (cg-RX-API-DMAC7.html)
EP (2) EP1958625A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008520696A (cg-RX-API-DMAC7.html)
KR (1) KR20070084325A (cg-RX-API-DMAC7.html)
CN (1) CN101083978A (cg-RX-API-DMAC7.html)
AR (1) AR052142A1 (cg-RX-API-DMAC7.html)
AT (1) ATE397442T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005306464A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518286A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588400A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005007376D1 (cg-RX-API-DMAC7.html)
DK (1) DK1817013T3 (cg-RX-API-DMAC7.html)
ES (1) ES2306278T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080349T3 (cg-RX-API-DMAC7.html)
IL (1) IL183116A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007005763A (cg-RX-API-DMAC7.html)
NO (1) NO20072388L (cg-RX-API-DMAC7.html)
PE (1) PE20061058A1 (cg-RX-API-DMAC7.html)
PL (1) PL1817013T3 (cg-RX-API-DMAC7.html)
PT (1) PT1817013E (cg-RX-API-DMAC7.html)
RU (1) RU2349319C1 (cg-RX-API-DMAC7.html)
SI (1) SI1817013T1 (cg-RX-API-DMAC7.html)
TW (1) TW200631609A (cg-RX-API-DMAC7.html)
WO (1) WO2006055740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703955B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
PT2835053T (pt) 2010-03-12 2016-07-14 Genzyme Corp Terapêutica combinada para o tratamento do cancro da mama
WO2012047802A2 (en) * 2010-10-01 2012-04-12 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
CA2826889C (en) 2011-02-11 2016-12-20 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CA2881992C (en) 2013-04-23 2016-11-22 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
AU720135B2 (en) * 1996-10-02 2000-05-25 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
KR100538095B1 (ko) * 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
CZ298027B6 (cs) * 1997-02-25 2007-05-30 Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
PT1117382E (pt) * 1998-10-01 2005-08-31 Powderject Res Ltd Microparticulas revestidas por pulverizacao para utilizacao em seringas sem agulha
NZ513268A (en) * 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
HK1038923B (en) * 1999-02-22 2004-03-19 Helmholtz-Zentrum Fur Infektionsforschung Gmbh C-21 modified EPOTHILONES
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
MXPA02003596A (es) * 2000-08-09 2003-10-14 Panacea Biotec Ltd Composiciones farmaceuticas novedosas de farmacos anti tubercular y procedimiento para su preparacion.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL154986A0 (en) * 2000-09-22 2003-10-31 Biotechnolog Forschung Gmbh Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE50008242D1 (de) 2000-09-26 2004-11-18 Enthone Omi Deutschland Gmbh Verfahren zur selektiven Metallisierung dielektrischer Materialien
KR100851719B1 (ko) * 2001-01-25 2008-08-11 브리스톨-마이어스스퀴브컴파니 암 치료용 에포틸론 유사체의 투여 방법
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
IL156988A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EP1368030A1 (en) * 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
SK11082003A3 (sk) * 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) * 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
HK1106713A1 (en) 2008-03-20
KR20070084325A (ko) 2007-08-24
PL1817013T3 (pl) 2009-01-30
PE20061058A1 (es) 2006-10-13
AU2005306464A1 (en) 2006-05-26
ATE397442T1 (de) 2008-06-15
WO2006055740A1 (en) 2006-05-26
EP1817013B1 (en) 2008-06-04
MX2007005763A (es) 2007-07-20
IL183116A0 (en) 2007-09-20
PT1817013E (pt) 2008-08-07
DK1817013T3 (da) 2008-10-13
EP1958625A1 (en) 2008-08-20
NO20072388L (no) 2007-06-14
RU2349319C1 (ru) 2009-03-20
TW200631609A (en) 2006-09-16
EP1817013A1 (en) 2007-08-15
HRP20080349T3 (hr) 2009-01-31
AR052142A1 (es) 2007-03-07
DE602005007376D1 (de) 2008-07-17
CN101083978A (zh) 2007-12-05
BRPI0518286A2 (pt) 2008-11-11
SI1817013T1 (sl) 2008-12-31
US20060153917A1 (en) 2006-07-13
CA2588400A1 (en) 2006-05-26
JP2008520696A (ja) 2008-06-19
ZA200703955B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
ES2241603T3 (es) Formulacion oral para la administracion al ileon que comprende un compuesto inhibidor del transporte de acidos biliares presentes en el ileon.
ES2306216T3 (es) Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
CN109646404B (zh) 葡萄糖激酶激活剂的口服制剂及其制备方法
US20060039981A1 (en) Taste masked dosage forms and processes for their preparation
CA2371912A1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CZ656388A3 (en) Pharmaceutical preparation consisting of granules containing tetracyclin compound
HRP20030674A2 (en) Pharmaceutical dosage forms of epothilones for oral administration
BRPI0721651B1 (pt) comprimido farmacêutico e usos deste na fabricação de um medicamento para tratamento de trombocitopenia e para agonizar o receptor tpo
CS270588B2 (en) Coating suitable for application on surface of pharmaceutical granules
HRP20020119A2 (en) Taste masked pharmaceutical liquid formulations
EA001760B1 (ru) Микрокапсулы, содержащие цис-платину
ES2306278T3 (es) Perla enterica recubierta que comprende ixabepilona.
ES3023309T3 (en) Dosage form comprising an alkaline agent and an enteric coating layer
ES2241478B1 (es) Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
ES2960331T3 (es) Composición farmacéutica de liberación prolongada de clozapina
US20130183433A1 (en) Stabilized picoplatin oral dosage form
BRPI0806418A2 (pt) formas de dosagem oral para picoplatina, série de granulados revestidos, processo para preparar uma forma de dosagem oral para picoplatina e métodos de tratamentos do cáncer
ES2271714T3 (es) Composicion farmaceutica para aplicacion oral y procedimiento de preparacion de la misma.
KR20100045528A (ko) 6-머캅토퓨린의 서방형 제제
ES2981041T3 (es) Formulación oral sólida de utidelona
HK1106713B (en) Enteric coated bead comprising ixabepilone
US20060134214A1 (en) Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
JPH0873345A (ja) 医薬製剤
CN101797238A (zh) 利福平在小肠上部释药制剂的制备及其特征
Chatterjee et al. A panoramic review on microparticles